Want to see FR:DBV full AI Analyst Report?
DBV Stock Chart & Stats
€2.38
€0.07(2.94%)
At close: 4:00 PM EDT
€2.38
€0.07(2.94%)
Day’s Range― - ―
52-Week Range€1.45 - €4.50
Previous CloseN/A
Volume603.12K
Average Volume (3M)1.12M
Market Cap
€799.62M
Enterprise Value€1.09K
Total Cash (Recent Filing)€174.90M
Total Debt (Recent Filing)€21.80M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Oct 28, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding314,375,400
10 Day Avg. Volume2,165,856
30 Day Avg. Volume1,121,838
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.18
Revenue Forecast (FY)€3.84M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Solid Balance SheetLow absolute debt versus sizable equity materially reduces near-term solvency risk and gives the company strategic flexibility. For a clinical-stage biotech this balance-sheet strength lengthens runway for trials, licensing or partnership negotiations without immediate refinancing pressure.
Proprietary EPIT Platform And Lead CandidateOwning a differentiated delivery platform (EPIT) and a lead clinical asset gives a durable product-development advantage. A platform approach can support multiple allergen programs, creating scalable pipeline optionality and potential for longer-term revenue streams if clinical/regulatory success is achieved.
Improving Free Cash Flow TrendAlthough FCF remains negative, a reported improvement in trailing free cash flow growth indicates progress in cost control or operational efficiency. That trend, if sustained, can extend runway, reduce future financing needs, and improve optionality for strategic deals over the medium term.
Bears Say
Large Ongoing Cash BurnSustained, very large operating and free cash outflows create a structural financing requirement. Over months this erodes cash reserves, forces dilutive raises or debt, and constrains discretionary spending. For a pre-revenue biotech this materially raises execution and funding risk.
Minimal And Volatile RevenueAlmost no recurring commercial revenue means the company remains dependent on trial outcomes, partnerships, or financing to create sustainable cash flow. Revenue volatility prevents operating leverage and complicates planning, leaving long-term viability contingent on clinical or licensing success.
Negative Returns Consuming Shareholder CapitalA negative ROE indicates the business is eroding rather than compounding shareholder value. Persistently negative profitability requires continual capital injections, increasing dilution risk and reducing long-term investor returns absent meaningful improvement in operations or successful commercialization.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.45 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €799.62M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Oct 28, 2026 which is in 68 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Jul 16, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of -€0.019 by -€0.002.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 314,375,400 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.021 in its last earnings report, missing expectations of -€0.019. Following the earnings report the stock price went down -7.275%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.